Chlamydia trachomatis and Neisseria gonorrhoeae by Transcription-Mediated Amplification (TMA), SurePath
SurePath media is not preferred when testing for Chlamydia trachomatis and Neisseria gonorrhoeae by transcription-mediated amplification (TMA). Use of transport media other than APTIMA specimen collection kit may result in reduced sensitivity. The preferred test is Chlamydia trachomatis and Neisseria gonorrhoeae by Transcription-Mediated Amplification (TMA) (0060241) or if confirmation of positive results by an alternate nucleic acid target is required, refer to Chlamydia trachomatis and Neisseria gonorrhoeae (CTNG) by Transcription-Mediated Amplification (TMA) with Reflex to CT/NG Confirmation (2011164).
New York DOH Approval Status
Cervical brush in SurePath liquid-based Pap test Media. Refer to "Sample Collection for the Diagnosis of STD" under Specimen Handling at www.aruplab.com for specific specimen collection and transport instructions.
Vortex SurePath media and transfer 1 mL to APTIMA Specimen Transfer Tube (ARUP supply #42711) within 24 hours of collection. Available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. To reduce the potential for contamination, SurePath specimens should be poured off, using sterile technique, into the APTIMA Specimen Transfer Tube prior to Cytology Testing.
Specimens in any container other than APTIMA Specimen Transfer Media. Specimens from patients that are less than 16 years of age.
Specimen source is required.
APTIMA Specimen Transfer Tube: Ambient: 2 weeks; Refrigerated: 1 month; Frozen: 1 month
Use of transport media other than the APTIMA specimen collection kit may result in reduced sensitivity. Specimens should be collected and transported following the instructions in "Sample Collection for the Diagnosis of STD Using Nucleic Acid Amplification Tests" under Specimen Handling at www.aruplab.com.
This test is intended for medical purposes only and is not valid for the evaluation of suspected sexual abuse or for other forensic purposes. In certain contexts, culture may be required to meet applicable laws and regulations for diagnosis of C. trachomatis and N. gonorrhoeae infections. Per 2014 CDC recommendations, this test does not include confirmation of positive results by an alternative nucleic acid target.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
|Component Test Code*||Component Chart Name||LOINC|
|2001552||C. trachomatis by TMA, SurePath||50387-0|
|2001553||N. gonorrhoeae by TMA, SurePath||50388-8|
- Chlamydia and GC TMA panel
- CT/GC TMA SurePath
- Gonorrhea SurePath
- Nucleic Acid Amplification Test (NAAT)